Michelle Barron, MD
Professor, Medicine-Infectious Disease
Medical School:
Department: Medicine-Infectious Disease
- MD, University of Texas Southwestern Medical Center at Dallas Southwestern Medical School (1996)
- BS, Yale University (CT) (1992)
- Creighton University Program (1997)
- Creighton University Program, Internal Medicine (1999)
- University of Colorado, Infectious Disease (2002)
Department: Medicine-Infectious Disease
Publications
- Embi PJ, Levy ME, Naleway AL, Patel P, Gaglani M, Natarajan K, Dascomb K, Ong TC, Klein NP, Liao IC, Grannis SJ, Han J, Stenehjem E, Dunne MM, Lewis N, Irving SA, Rao S, McEvoy C, Bozio CH, Murthy K, Dixon BE, Grisel N, Yang DH, Goddard K, Kharbanda AB, Reynolds S, Raiyani C, Fadel WF, Arndorfer J, Rowley EA, Fireman B, Ferdinands J, Valvi NR, Ball SW, Zerbo O, Griggs EP, Mitchell PK, Porter RM, Kiduko SA, Blanton L, Zhuang Y, Steffens A, Reese SE, Olson N, Williams J, Dickerson M, McMorrow M, Schrag SJ, Verani JR, Fry AM, Azziz-Baumgartner E, Barron MA, Thompson MG, DeSilva MB. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 5;70(44):1553-1559. PubMed PMID: 34735426
- Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, DeSilva MB, Natarajan K, Bozio CH, Lewis N, Dascomb K, Dixon BE, Birch RJ, Irving SA, Rao S, Kharbanda E, Han J, Reynolds S, Goddard K, Grisel N, Fadel WF, Levy ME, Ferdinands J, Fireman B, Arndorfer J, Valvi NR, Rowley EA, Patel P, Zerbo O, Griggs EP, Porter RM, Demarco M, Blanton L, Steffens A, Zhuang Y, Olson N, Barron M, Shifflett P, Schrag SJ, Verani JR, Fry A, Gaglani M, Azziz-Baumgartner E, Klein NP. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N Engl J Med. 2021 Oct 7;385(15):1355-1371. PubMed PMID: 34496194
- Bozio CH, Grannis SJ, Naleway AL, Ong TC, Butterfield KA, DeSilva MB, Natarajan K, Yang DH, Rao S, Klein NP, Irving SA, Dixon BE, Dascomb K, Liao IC, Reynolds S, McEvoy C, Han J, Reese SE, Lewis N, Fadel WF, Grisel N, Murthy K, Ferdinands J, Kharbanda AB, Mitchell PK, Goddard K, Embi PJ, Arndorfer J, Raiyani C, Patel P, Rowley EA, Fireman B, Valvi NR, Griggs EP, Levy ME, Zerbo O, Porter RM, Birch RJ, Blanton L, Ball SW, Steffens A, Olson N, Williams J, Dickerson M, McMorrow M, Schrag SJ, Verani JR, Fry AM, Azziz-Baumgartner E, Barron M, Gaglani M, Thompson MG, Stenehjem E. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 5;70(44):1539-1544. PubMed PMID: 34735425
- Goss FR, Bookman K, Barron M, Bickley D, Landgren B, Kroehl M, Williamson K, Zane R, Wiler J. Improved antibiotic prescribing using indication-based clinical decision support in the emergency department. J Am Coll Emerg Physicians Open. 2020 Jun;1(3):214-221. PubMed PMID: 33000036
- King M, Hurley H, Davidson KR, Dempsey EC, Barron MA, Chan ED, Frey A. The Link between Fusobacteria and Colon Cancer: a Fulminant Example and Review of the Evidence. Immune Netw. 2020 Aug;20(4):e30. PubMed PMID: 32895617
- Mann S, Tobolowsky F, Purohit S, Henao-Martínez A, Bajrovic V, Ramanan P, Wolfel E, Khazanie P, Barron M, Madinger N, Benamu E. Cryptococcal pericarditis in a heart transplant recipient. Transpl Infect Dis. 2020 Dec;22(6):e13366. PubMed PMID: 32533755
- Lodise TP, Rosenkranz SL, Finnemeyer M, Evans S, Sims M, Zervos MJ, Creech CB, Patel PC, Keefer M, Riska P, Silveira FP, Scheetz M, Wunderink RG, Rodriguez M, Schrank J, Bleasdale SC, Schultz S, Barron M, Stapleton A, Wray D, Chambers H, Fowler VG, Holland TL. The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE). Clin Infect Dis. 2020 Apr 10;70(8):1536-1545. PubMed PMID: 31157370
- Miller MA, Fish DN, Barber GR, Barron MA, Goolsby TA, Moine P, Mueller SW. A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections. J Microbiol Immunol Infect. 2020 Apr;53(2):321-327. PubMed PMID: 30190234
- Lodise TP, Rosenkranz SL, Finnemeyer M, Evans S, Sims M, Zervos MJ, Creech CB, Patel PC, Keefer M, Riska P, Silveira FP, Scheetz M, Wunderink RG, Rodriguez M, Schrank J, Bleasdale SC, Schultz S, Barron M, Stapleton A, Wray D, Chambers H, Fowler V, Holland TL. The Emperor's New Clothes: Prospective Observational Evaluation of the Association between Initial Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections (PROVIDE). Clin Infect Dis. 2019 Jun 3. [Epub ahead of print] PubMed PMID: 31157370
- Miller MA, Fish DN, Barber GR, Barron MA, Goolsby TA, Moine P, Mueller SW. A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections. J Microbiol Immunol Infect. 2018 Aug 18. [Epub ahead of print] PubMed PMID: 30190234
- Barron MA, Richardson K, Jeffres M, McCollister B. Risk factors and influence of carbapenem exposure on the development of carbapenem resistant Pseudomonas aeruginosa bloodstream infections and infections at sterile sites. Springerplus. 2016 Jun 17;5(1):755. PubMed PMID: 27386239
- Shah NS, Greenberg JA, McNulty MC, Gregg KS, Riddell J 4th, Mangino JE, Weber DM, Hebert CL, Marzec NS, Barron MA, Chaparro-Rojas F, Restrepo A, Hemmige V, Prasidthrathsint K, Cobb S, Herwaldt L, Raabe V, Cannavino CR, Hines AG, Bares SH, Antiporta PB, Scardina T, Patel U, Reid G, Mohazabnia P, Kachhdiya S, Le BM, Park CJ, Ostrowsky B, Robicsek A, Smith BA, Schied J, Bhatti MM, Mayer S, Sikka M, Murphy-Aguilu I, Patwari P, Abeles SR, Torriani FJ, Abbas Z, Toya S, Doktor K, Chakrabarti A, Doblecki-Lewis S, Looney DJ, David MZ. Bacterial and viral co-infections complicating severe influenza: Incidence and impact among 507 U.S. patients, 2013-14. J Clin Virol. 2016 Jul;80:12-9. PubMed PMID: 27130980
- Barron MA, Frank DN, Claypool D, Ir D, Ning MF, Curtis D, Weinberg A. Antibody responses to influenza a H1N1 vaccine compared to the circulating strain in influenza vaccine recipients during the 2013/2014 season in North America. J Clin Virol. 2016 Oct;83:56-60. PubMed PMID: 27591557
- Shah NS, Greenberg JA, McNulty MC, Gregg KS, Riddell J, Mangino JE, Weber DM, Hebert CL, Marzec NS, Barron MA, Chaparro-Rojas F, Restrepo A, Hemmige V, Prasidthrathsint K, Cobb S, Herwaldt L, Raabe V, Cannavino CR, Hines AG, Bares SH, Antiporta PB, Scardina T, Patel U, Reid G, Mohazabnia P, Kachhdiya S, Le BM, Park CJ, Ostrowsky B, Robicsek A, Smith BA, Schied J, Bhatti MM, Mayer S, Sikka M, Murphy-Aguilu I, Patwari P, Abeles SR, Torriani FJ, Abbas Z, Toya S, Doktor K, Chakrabarti A, Doblecki-Lewis S, Looney DJ, David MZ. Severe Influenza in 33 US Hospitals, 2013-2014: Complications and Risk Factors for Death in 507 Patients. Infect Control Hosp Epidemiol. 2015 Nov;36(11):1251-60. PubMed PMID: 26224364
- Gerding DN, Meyer T, Lee C, Cohen SH, Murthy UK, Poirier A, Van Schooneveld TC, Pardi DS, Ramos A, Barron MA, Chen H, Villano S. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA. 2015 May 5;313(17):1719-27. PubMed PMID: 25942722
- Barron MA, Leung DY. Lessons from Ebola and readiness for new emerging infectious threats. J Allergy Clin Immunol. 2015 Apr;135(4):872-4. PubMed PMID: 25843599
- Faubel S, Franch H, Vijayan A, Barron MA, Heung M, Liu KD, Koyner JL, Conner MJ Jr. Preparing for renal replacement therapy in patients with the Ebola virus disease. Blood Purif. 2014;38(3-4):276-85. PubMed PMID: 25675963
- Singh N, Suarez JF, Avery R, Lass-Flörl C, Geltner C, Pasqualotto AC, Lyon GM, Barron M, Husain S, Wagener MM, Montoya JG. Immune reconstitution syndrome-like entity in lung transplant recipients with invasive aspergillosis. Transpl Immunol. 2013 Dec;29(1-4):109-13. PubMed PMID: 24076039
- Henao-Martínez AF, Castillo-Mancilla JR, Barron MA, Nichol AC. Combination Antifungal Therapy in the Treatment of Scedosporium apiospermum Central Nervous System Infections. Case Rep Infect Dis. 2013;2013:589490. PubMed PMID: 23738164
- Singh N, Suarez JF, Avery R, Lass-Flörl C, Geltner C, Pasqualotto AC, Marshall Lyon G, Barron M, Husain S, Wagener MM, Montoya JG. Risk factors and outcomes in lung transplant recipients with nodular invasive pulmonary aspergillosis. J Infect. 2013 Jul;67(1):72-8. PubMed PMID: 23567625
- Golightly LK, Barber GR, Barron MA, Page RL 2nd. Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability. Drug Metabol Drug Interact. 2013;28(1):49-58. PubMed PMID: 23314530
Practice Locations
UCHealth Anschutz Outpatient Pavilion - Anschutz Medical Campus
1635 Aurora Ct
Aurora, CO 80045
720-848-0000
UCHealth Infectious Disease Clinic - Anschutz Medical Campus
1635 Aurora Ct
7th Floor
Aurora, CO 80045
720-848-0191
Hospital Affiliation
1635 Aurora Ct
Aurora, CO 80045
720-848-0000
UCHealth Infectious Disease Clinic - Anschutz Medical Campus
1635 Aurora Ct
7th Floor
Aurora, CO 80045
720-848-0191
Hospital Affiliation
- University of Colorado Hospital
Specialty Information
Specialties
- Infectious Disease, Board Certification (2010)
- Internal Medicine, Board Certification (2011)
Care Philosophy
Dr. Michelle Barron is the senior medical director of infection prevention and control for UCHealth, a nationally recognized health care system with operating revenue of $5.0 billion, a workforce of more than 25,000 people and 12 hospitals, including the state’s only academic medical center. As one of the top infectious disease experts in Colorado, she brings her expertise to the entire UCHealth system, working from UCHealth University of Colorado Hospital on the Anschutz Medical Campus. After graduating from Yale in 1992, she returned to her home state of Texas for medical school at the University of Texas Southwestern Medical Center in Dallas. While there, Dr. Barron found her calling in infectious disease while treating people affected by AIDS. She then completed her internship and residency program at Creighton University before coming to Colorado in 1999 to begin her fellowship at the University of Colorado. For much of her career at University of Colorado Hospital, Dr. Barron has served as medical director of infection prevention and control. She is board certified in infectious disease and internal medicine. She’s also a professor at the University of Colorado School of Medicine. Dr. Barron has led the charge against infectious diseases including the H1N1 flu pandemic in 2009 and Ebola in 2015. Since January 2020 and the beginning of the COVID-19 pandemic, she has worked around the clock with fellow leaders to protect patients, staff and providers across UCHealth. Her message has always been comforting and clear; “This is what we do. We take care of sick patients. We know how to do this.” While coping with the pandemic, Dr. Barron has kept twin missions top of mind; providing extraordinary care to patients while protecting caregivers. Dr. Barron is also a member of the Colorado Governor’s Expert Emergency Epidemic Response Committee (GEEERC). When Dr. Barron isn’t tackling infectious diseases and pandemics, you can find her traveling the globe with her husband Greg, playing with her dog Chase and inspiring others with her trademark positivity and strength.
Dr. Michelle Barron is the senior medical director of infection prevention and control for UCHealth, a nationally recognized health care system with operating revenue of $5.0 billion, a workforce of more than 25,000 people and 12 hospitals, including the state’s only academic medical center. As one of the top infectious disease experts in Colorado, she brings her expertise to the entire UCHealth system, working from UCHealth University of Colorado Hospital on the Anschutz Medical Campus. After graduating from Yale in 1992, she returned to her home state of Texas for medical school at the University of Texas Southwestern Medical Center in Dallas. While there, Dr. Barron found her calling in infectious disease while treating people affected by AIDS. She then completed her internship and residency program at Creighton University before coming to Colorado in 1999 to begin her fellowship at the University of Colorado. For much of her career at University of Colorado Hospital, Dr. Barron has served as medical director of infection prevention and control. She is board certified in infectious disease and internal medicine. She’s also a professor at the University of Colorado School of Medicine. Dr. Barron has led the charge against infectious diseases including the H1N1 flu pandemic in 2009 and Ebola in 2015. Since January 2020 and the beginning of the COVID-19 pandemic, she has worked around the clock with fellow leaders to protect patients, staff and providers across UCHealth. Her message has always been comforting and clear; “This is what we do. We take care of sick patients. We know how to do this.” While coping with the pandemic, Dr. Barron has kept twin missions top of mind; providing extraordinary care to patients while protecting caregivers. Dr. Barron is also a member of the Colorado Governor’s Expert Emergency Epidemic Response Committee (GEEERC). When Dr. Barron isn’t tackling infectious diseases and pandemics, you can find her traveling the globe with her husband Greg, playing with her dog Chase and inspiring others with her trademark positivity and strength.
General Information
Medical Schools:
- MD, University of Texas Southwestern Medical Center at Dallas Southwestern Medical School (1996)
Undergraduate Schools:
- BS, Yale University (CT) (1992)
Internships:
- Creighton University Program (1997)
Residency Programs:
- Creighton University Program, Internal Medicine (1999)
Fellowships:
- University of Colorado, Infectious Disease (2002)
Department: Medicine-Infectious Disease